Skip to content

Novocure

US · NVCR #2889 by market cap Listed 2015
10.71 +0.02 +0.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 10.58 -1.03%
After-hours 10.71 0.00%
19.9910.6910.712026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on NVCR?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -23.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 11.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth C

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 6.8% Better than 54%
Free cash flow CAGR (3Y) -16.4% Better than 22%
Profitability C-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 74.5% Better than 87%
Operating margin -23.5% Better than 12%
Net margin -20.8% Better than 12%
Return on equity -38.9% Better than 11%
Return on invested capital -16.2% Better than 15%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -37.4% Better than 12%
6-month return -40.4% Better than 12%
12-month return (ex latest month) 22.8% Better than 62%
Distance below 52-week high 50.1% Better than 18%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.9x Better than 72%
Debt to assets 30.9% Better than 40%
Interest coverage -7.0x Better than 15%
Free cash flow / net income 425.0% Better than 91%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 149.0% Better than 90%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -9.47%
1M -31.83%
3M -39.73%
6M -39.66%
YTD -17.17%
1Y -6.54%
3Y -12.14%
5Y -89.65%

Key statistics

Price & volume

Prev close
10.69
Open
10.61
Day range
10.61 - 11.06
Avg price
10.76
Volume
1.64M
Turnover
17.63M
Amplitude
4.16%
52-week range
9.82 - 21.45

Valuation

P/E
-8.78
P/E (TTM)
-10.10
P/B
3.57
EPS
-1.22
Net profit
-142.64M
Net assets
350.63M

Share structure

Market cap
1.25B
Float cap
1.04B
Shares out
116.92M
Float shares
97.39M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2015-10-02
52-week range 8% of range
9.82 21.45

50.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-7.14M net over the window

Short interest

Shares short
12.91M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Novocure (NVCR)?

Novocure last traded at 10.71. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Novocure's market cap?

About 1.25B.

What is the P/E ratio of Novocure?

The trailing twelve-month P/E is -10.10. The Valuation tab shows it against the stock's own five-year range.

Does Novocure pay a dividend?

Novocure does not currently pay a regular dividend.

Is Novocure a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 26.67, which implies 149.0% upside from the current price. This is not investment advice.

What is Novocure's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Novocure a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Novocure discussion 0 comments

Add a comment